This page ranks research hypotheses in neurodegenerative diseases based on evidence strength, therapeutic potential, and current research activity. Rankings are based on: recent publication count, journal impact, GWAS support, biomarker validation, trial activity, and novelty.
| Criterion | Weight | Description |
|---|---|---|
| Recent Publications (2024-2026) | 20% | Publication count and growth rate |
| Journal Impact | 15% | Average impact factor of publishing journals |
| GWAS Support | 15% | Genetic evidence strength |
| Biomarker Validation | 15% | Clinical biomarker development |
| Trial Activity | 15% | Number and phase of clinical trials |
| Novelty | 20% | Underserved area with potential |
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | Amyloid-beta aggregation | 85 | 95 | 90 | 95 | 90 | 85 | 45 |
| 2 | Tau pathology | 82 | 90 | 88 | 90 | 85 | 75 | 50 |
| 3 | Neuroinflammation | 72 | 80 | 72 | 70 | 65 | 60 | 75 |
| 4 | Synaptic dysfunction | 65 | 60 | 65 | 55 | 70 | 45 | 80 |
| 5 | Metabolic dysfunction (Type 3 Diabetes) | 65 | 68 | 62 | 70 | 58 | 52 | 60 |
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | Microbiome-Gut-Brain Axis | 72 | 85 | 70 | 55 | 62 | 52 | 85 |
| 2 | Porphyromonas gingivalis / Infectious | 68 | 78 | 72 | 50 | 58 | 50 | 80 |
| 3 | Cellular Senescence in AD | 62 | 65 | 68 | 42 | 58 | 42 | 85 |
| 4 | Vascular/BBB Dysfunction | 58 | 62 | 60 | 52 | 58 | 48 | 70 |
bfe67bb53c3c532ef4237fa3323691ae27404769
| 6 | Circadian-Glymphatic-Metabolic Coupling Failure | 54 | 55 | 60 | 35 | 50 | 30 | 88 |
| 7 | Metal-Ion / Ferroptosis Dysfunction | 52 | 55 | 58 | 48 | 55 | 38 | 78 |
| 8 | Epigenetic Dysregulation in AD | 48 | 52 | 58 | 42 | 48 | 32 | 82 |
| 9 | Iron-Calcium-Glymphatic Convergence | 58 | 55 | 58 | 42 | 60 | 35 | 85 |
| 10 | Environmental (Heavy metals, air pollution) | 40 | 42 | 45 | 32 | 32 | 28 | 70 |
| 11 | Brain Hyperconnectivity-Tau Spread | 45 | 48 | 52 | 40 | 35 | 28 | 72 |
| 12 | Neural Stem Cell Failure | 52 | 62 | 55 | 42 | 52 | 45 | 85 |
↑ indicates score increase from new evidence (2025-2026)
Status: Dominant paradigm, but recent trial failures suggest need for combination therapy
Strength: Strong genetic (APP, PSEN1/2), biochemical, biomarker (CSF Aβ42)
Weakness: Limited therapeutic efficacy to date
Status: Secondary pathology strongly correlated with cognitive decline
Strength: Strong neuropathology, tau PET imaging, NFT spread patterns
Weakness: Less clear if primary driver or downstream effect
Status: Key cross-cutting mechanism with growing evidence
Strength: Microglia imaging (TSPO PET), genetic (TREM2), complements
Weakness: Complex, pleiotropic pathways
Status: Rapidly growing area with strong 2025-2026 evidence
Strength: SCFA mechanisms, A. muciniphila, indole-3-propionate, B. ovatus, pathobiome theory
Weakness: Human translation limited; causality unclear
Status: Strong new evidence in 2025-2026, under-tested
Strength: P. gingivalis impairs microglial Aβ clearance, kynurenine pathway, IFITM3-Aβ axis, OMVs in zebrafish model
Weakness: Causality not fully established; requires clinical trials
Status: Newly synthesized — integrates four mechanisms under circadian master regulator
Strength: Unifies circadian clock, glymphatic clearance, orexin signaling, and metabolic coupling; high mechanistic coherence; sleep therapies already clinically available
Weakness: Low GWAS support; limited direct evidence for clock as upstream driver; orexin modulation approaches still experimental
Novelty: 88/100 — addresses gap in rankings; circadian dysfunction is severely under-tested in AD
Status: Newly synthesized — integrates iron, calcium, and glymphatic dysfunction into unified triad
Strength: Anchors iron as upstream driver; explains glymphatic impairment via astrocyte dysfunction; QSM MRI and DTI-ALPS provide biomarker pathway
Weakness: Iron chelation trials limited; calcium channel targets poorly validated for this indication; requires multimodal imaging to test
Novelty: 85/100 — convergence hypothesis not previously synthesized; bridges metal-ion and sleep-glymphatic domains
Score: 65 (high novelty, now with strong evidence)
This hypothesis integrates three interconnected mechanisms:
Key insight: Periodontal disease may be a modifiable risk factor for AD through the systemic inflammation-gut-brain axis. Recent 2025 studies demonstrate:
Prediction: Periodontal disease treatment + gut microbiome modulation + anti-inflammatory will show greater efficacy than single-target approaches.
Testable predictions:
Synthesized: 2026-03-21 18:10 PT by Slot 6
Updated with new 2025-2026 evidence
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | Alpha-synuclein aggregation & propagation | 88 | 95 | 90 | 92 | 85 | 80 | 60 |
| 2 | LRRK2 pathogenesis | 78 | 85 | 82 | 90 | 72 | 65 | 55 |
| 3 | GBA-associated neurodegeneration | 74 | 80 | 78 | 88 | 70 | 58 | 60 |
| 4 | Mitochondrial dysfunction (PINK1/PARKIN) | 72 | 78 | 75 | 85 | 65 | 60 | 55 |
| 5 | Neuroinflammation (Microglia/TREM2) | 70 | 82 | 74 | 75 | 68 | 55 | 65 |
| 6 | Gut-brain axis & α-syn propagation | 68 | 78 | 70 | 62 | 60 | 52 | 75 |
| 7 | Lysosomal/autophagy dysfunction | 66 | 72 | 68 | 78 | 58 | 50 | 60 |
| 8 | Synaptic vesicle trafficking dysfunction | 62 | 65 | 64 | 58 | 55 | 45 | 70 |
Status: Central to PD pathogenesis, supported by genetic, neuropathological, and biomarker evidence
Strength: Lewy bodies, SNCA mutations/f duplications, prion-like propagation, seeding assays
Weakness: Initiating trigger unknown; therapeutic targeting challenging
Status: Major genetic risk factor, especially for familial PD
Strength: Kinase hyperactivity, GWAS significance, therapeutic target (LRRK2 inhibitors in trials)
Weakness: Incomplete understanding of downstream effects
Status: Most common genetic risk factor for sporadic PD
Strength: Lysosomal dysfunction mechanism, carrier frequency, enzyme replacement potential
Weakness: Variable penetrance, complex genotype-phenotype
Status: Early-onset autosomal recessive PD
Strength: Mitophagy pathway, PARK2/6/9 genes, toxin models
Weakness: Monogenic form may not represent sporadic PD
Status: Cross-cutting mechanism in PD progression
Strength: TSPO PET imaging, TREM2 genetics, cytokine biomarkers
Weakness: Bidirectional relationship unclear
Status: Emerging area with strong anatomical rationale
Strength: Vagal nerve connections, gut α-syn, microbiome differences
Weakness: Causality not established; human translation limited
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | TDP-43 proteinopathy | 90 | 95 | 92 | 88 | 85 | 80 | 55 |
| 2 | C9orf72 hexanucleotide repeat toxicity | 85 | 92 | 88 | 95 | 80 | 75 | 50 |
| 3 | Glutamate excitotoxicity | 78 | 85 | 80 | 70 | 75 | 85 | 45 |
| 4 | RNA metabolism dysfunction | 74 | 80 | 78 | 82 | 68 | 55 | 60 |
| 5 | Mitochondrial dysfunction | 72 | 78 | 74 | 75 | 65 | 60 | 55 |
| 6 | Astrocyte-mediated toxicity | 68 | 75 | 70 | 68 | 62 | 50 | 70 |
| 7 | Neuroinflammation (Microglia) | 66 | 72 | 68 | 65 | 60 | 52 | 72 |
| 8 | Impaired autophagy/proteostasis | 64 | 70 | 66 | 72 | 58 | 48 | 65 |
Status: Pathological hallmark in 97% of ALS cases (including sporadic)
Strength: Ubiquitinated inclusions, TDP-43 mutations, stress granules
Weakness: Mechanism of toxicity unclear; therapeutic targets ill-defined
Status: Most common genetic cause of familial ALS/FTD
Strength: RNA foci, dipeptide repeat proteins, nucleocytoplasmic transport disruption
Weakness: Heterogeneous disease presentation; multiple mechanisms
Status: Well-established mechanism with approved therapy
Strength: Riluzole approved, EAAT2 dysfunction, magnesium studies
Weakness: Modest clinical benefit; need for combination approaches
Status: Central to ALS pathogenesis
Strength: TDP-43, FUS, ATXN2; splicing defects
Weakness: Downstream effects complex; difficult to target
Status: Emerging non-cell-autonomous mechanism
Strength: Astrocyte-neuron co-culture models, EAAT2 loss
Weakness: Therapeutic targeting challenging; need for in vivo models
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | Tau proteinopathy (3R/4R) | 82 | 88 | 85 | 80 | 78 | 70 | 55 |
| 2 | TDP-43 proteinopathy (Type A/B/C) | 80 | 86 | 82 | 78 | 75 | 65 | 60 |
| 3 | FUS proteinopathy | 72 | 78 | 76 | 75 | 68 | 55 | 62 |
| 4 | GRN (Progranulin) haploinsufficiency | 70 | 76 | 74 | 82 | 65 | 58 | 58 |
| 5 | C9orf72 expansion (FTD/ALS overlap) | 68 | 75 | 72 | 80 | 62 | 50 | 55 |
| 6 | Neuroinflammation | 62 | 68 | 64 | 60 | 55 | 45 | 70 |
Status: Dominant in Pick's disease, PSP, CBD
Strength: 3R/4R tau isoforms,NFT formation, MAPT mutations
Weakness: Heterogeneous tauopathies; treatment beyond tauopathy-AD overlap
Status: Major pathology in sporadic FTD (60%)
Strength: Type A/B/C subtypes, GRN/C9orf72 links
Weakness: Overlap with ALS complicates interpretation
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | Mutant huntingtin (mHTT) toxic gain-of-function | 85 | 90 | 85 | 95 | 82 | 65 | 50 |
| 2 | Transcriptional dysregulation (REST/NCoR/BDNF) | 78 | 82 | 80 | 85 | 70 | 55 | 55 |
| 3 | Mitochondrial dysfunction (fission/fusion/bioenergetics) | 76 | 80 | 78 | 82 | 68 | 58 | 55 |
| 4 | Striatal selective vulnerability (MSN degeneration) | 72 | 75 | 76 | 70 | 72 | 50 | 65 |
| 5 | Somatic CAG repeat expansion (DNA repair modifiers) | 70 | 78 | 72 | 65 | 60 | 45 | 80 |
| 6 | Synaptic dysfunction (corticostriatal transmission) | 68 | 72 | 70 | 62 | 65 | 48 | 62 |
| 7 | Autophagy/proteostasis impairment (aggregate clearance) | 66 | 70 | 68 | 75 | 58 | 52 | 60 |
| 8 | Excitotoxicity (NMDA calcium dysregulation) | 60 | 62 | 60 | 55 | 55 | 45 | 58 |
Status: Causative, central to all HD pathogenesis
Strength: Causal mutation (HTT CAG repeat), polyQ tract toxicity, inclusion bodies, allele-specific silencing trials
Weakness: Downstream mechanisms diverse; onset doesn't correlate perfectly with CAG length alone
Status: Major downstream effect of mHTT
Strength: REST sequestration, NCoR/mSin3 loss, BDNF reduction, genome-wide dysregulation studies
Weakness: Secondary to mHTT; therapeutic targeting indirect
Status: Well-established early event in HD pathogenesis
Strength: Impaired fission/fusion, reduced complex IV, mtDNA deletions, PGC-1alpha dysregulation
Weakness: Confounded by downstream effects of transcriptional dysregulation
Status: Pathological hallmark — why MSNs specifically degenerate
Strength: Medium spiny neuron degeneration, corticostriatal synaptic vulnerability, DARPP32 loss
Weakness: Mechanism of selective vulnerability unclear; mHTT is ubiquitous
Status: Emerging critical modifier of disease progression
Strength: FAN1, LIG1, MSH3 GWAS modifiers; somatic expansion in HD brains; DNA repair target
Weakness: Mechanistic details incomplete; causality in humans still being established
Status: Key functional consequence of mHTT toxicity
Strength: Dendritic spine loss, neurotransmitter release deficits, corticostriatal circuit dysfunction
Weakness: Overlaps with other mechanisms; correlation vs causation
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | Alpha-synuclein aggregation & cortical propagation | 85 | 88 | 88 | 85 | 82 | 70 | 55 |
| 2 | Lewy body distribution pattern (cortical > brainstem) | 78 | 80 | 78 | 72 | 75 | 55 | 58 |
| 3 | Cholinergic deficit (basal forebrain/subcortical) | 72 | 75 | 76 | 68 | 78 | 65 | 55 |
| 4 | REM sleep behavior disorder as prodromal marker | 70 | 72 | 70 | 55 | 80 | 45 | 70 |
| 5 | Cognitive fluctuation (thalamocortical dysconnectivity) | 65 | 62 | 64 | 50 | 68 | 42 | 72 |
| 6 | Neuroinflammation (microglial activation in DLB) | 58 | 60 | 58 | 52 | 50 | 38 | 68 |
| 7 | Visual hallucinations (attentional network dysfunction) | 55 | 58 | 55 | 45 | 60 | 35 | 65 |
Status: Central pathology shared with PD but with distinct cortical predominance
Strength: LB pathology in cortical/subcortical regions, SNCA duplications, seeding assays, prion-like spread
Weakness: Initiating trigger unknown; why cortical vs brainstem-first presentation differs
Status: Neuropathological basis for DLB clinical phenotype
Strength: Diffuse cortical LBs, limbic LBs, brainstem involvement; McKeith criteria
Weakness: Limited inter-rater reliability; distribution overlaps with PDD
Status: More severe cholinergic loss than AD; key therapeutic target
Strength: Basal forebrain neuron loss, ChAT reduction, cholinesterase inhibitor efficacy
Weakness: Secondary to synuclein pathology; symptomatic only
Status: Strong prodromal indicator with decades of latency
Strength: iRBD converts to DLB/PD at high rates; synuclein deposition precedes symptoms
Weakness: Not all DLB patients have iRBD; mechanism of sleep disruption unclear
Status: Core DLB feature with unclear pathophysiology
Strength: Attentional network failure, thalamocortical dysconnectivity, EEG slowing
Weakness: Subjective; poorly correlated with neuroimaging
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | Alpha-synuclein glial cytoplasmic inclusions (GCI) | 88 | 90 | 88 | 82 | 85 | 75 | 50 |
| 2 | Oligodendrocyte dysfunction & myelin pathology | 82 | 85 | 82 | 78 | 80 | 65 | 55 |
| 3 | Neuronal alpha-synuclein pathology (secondary) | 72 | 75 | 74 | 65 | 70 | 52 | 62 |
| 4 | Autonomic failure (cardiovascular/urinary) | 78 | 82 | 76 | 72 | 85 | 55 | 50 |
| 5 | α-Syn propagation (oligodendrocyte-to-neuron) | 68 | 72 | 70 | 60 | 62 | 48 | 75 |
Status: Pathological hallmark — defines MSA neuropathologically
Strength: GCI in oligodendrocytes, SNCA accumulation, seeding capability, diagnostic specificity
Weakness: Why oligodendrocytes specifically in MSA vs neurons in PD
Status: Primary pathology in MSA — myelin loss precedes neuronal death
Strength: Oligodendrocyte vulnerability, MBP reduction, remyelination failure, CNS myelin dysfunction
Weakness: Secondary to α-syn accumulation or primary trigger?
Status: Core clinical feature defining MSA
Strength: Central and peripheral autonomic pathways, preganglionic sympathetic neurons, baroreflex failure
Weakness: Mechanism of selective vulnerability in autonomic neurons unclear
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | 4R tau aggregation (NFTs, coiled bodies) | 88 | 90 | 90 | 92 | 88 | 80 | 45 |
| 2 | Astrocytic tau pathology (tufted astrocytes) | 78 | 82 | 80 | 78 | 72 | 58 | 58 |
| 3 | Brainstem vulnerability (oculomotor/PPRF/PPN) | 80 | 85 | 82 | 75 | 78 | 62 | 52 |
| 4 | Tau propagation (network-based spreading) | 72 | 78 | 75 | 72 | 70 | 55 | 62 |
| 5 | Neuroinflammation (microglial activation) | 62 | 65 | 64 | 58 | 55 | 45 | 70 |
| 6 | Oligodendrocyte pathology (coiled bodies) | 70 | 72 | 70 | 65 | 62 | 48 | 60 |
Status: Defining pathology of PSP — 4R tau exclusively
Strength: NFTs, tufted astrocytes, coiled bodies; MAPT H1/H1 association; tau PET tracers
Weakness: Why 4R specifically; initiating events unknown
Status: Explains core clinical features
Strength: Oculomotor nucleus, PPRF, pedunculopontine nucleus degeneration; vertical gaze palsy
Weakness: Network-wide involvement; brainstem-first vs cortical-first variants
Status: Pathognomonic for PSP (tufted astrocytes)
Strength: Distinct from AD; tau aggregation in astrocytes; selective vulnerability of specific astrocyte types
Weakness: Mechanism of astrocyte-specific tau pathology; contribution to neuronal death unclear
| Rank | Hypothesis | Total Score | Pub | IF | GWAS | Biomarker | Trials | Novelty |
|---|---|---|---|---|---|---|---|---|
| 1 | 4R tau pathology (cortical/basal ganglia) | 78 | 82 | 80 | 78 | 75 | 58 | 55 |
| 2 | Asymmetric cortical degeneration (frontoparietal) | 75 | 78 | 76 | 70 | 72 | 52 | 58 |
| 3 | Astrocyte pathology (tufted-like inclusions) | 65 | 68 | 65 | 60 | 58 | 42 | 65 |
| 4 | Nigrostriatal dysfunction | 70 | 72 | 70 | 65 | 68 | 50 | 55 |
| 5 | Neuroinflammation (asymmetric microglial activation) | 58 | 60 | 58 | 52 | 50 | 38 | 68 |
| 6 | Cell-to-cell tau propagation | 62 | 65 | 62 | 58 | 55 | 45 | 65 |
Status: Dominant pathology — overlap with PSP
Strength: 4R tau inclusions, astrocytic plaques, CBS-PSP tau PET overlap
Weakness: CBS is a clinical syndrome with heterogeneous pathology (50%+ CBD pathology, rest PSP, AD, others)
Status: Clinical hallmark of CBS — explains unilateral signs
Strength: Asymmetric frontoparietal atrophy, alien limb, apraxia; imaging correlates
Weakness: Pathological substrate varies; not all CBS has asymmetric tau
| Score | Description |
|---|---|
| 9-10 | Clearly testable with current methods; clear experimental predictions |
| 7-8 | Testable with reasonable approach; some methodological challenges |
| 5-6 | Partially testable; requires significant methodological development |
| 3-4 | Difficult to test with current technology |
| 1-2 | Currently untestable |
| Score | Description |
|---|---|
| 9-10 | Clear druggable target; multiple therapeutic modalities possible |
| 7-8 | Actionable target; some therapeutic approaches in development |
| 5-6 | Target identified but challenging to modulate |
| 3-4 | Target unclear; limited therapeutic angles |
| 1-2 | No clear therapeutic pathway identified |
Note: PD, ALS, FTD hypothesis rankings added 2026-03-28. HD, DLB, MSA, PSP, CBS rankings added 2026-03-29.
All major neurodegenerative diseases now have hypothesis rankings.